Clinical Trial Update: Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib/dexamethasone therapy in relapsed/refractory cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• bortezomib/dexamethasone

Snippet

Sponsor: Samsung Medical Center | Conditions: Relapsed and/or Refractory Cutaneous T-cell Lymphoma | Phase 2 | Status: COMPLETED